¼¼°èÀÇ ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå ºÐ¼®°ú ¿¹Ãø(-2033³â) : À¯Çü, Á¦Ç°, ¼­ºñ½º, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ÇüÅÂ, ½ºÅ×ÀÌÁö
Allergy Therapeutics Market Analysis and Forecast to 2033: Type, Product, Services, Technology, Application, End User, Mode, Stage
»óǰÄÚµå : 1633883
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 380 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,872,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,319,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,766,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â CAGR 7.3%¸¦ ¹Ý¿µÇÏ¿© 2023³â 217¾ï ´Þ·¯¿¡¼­ 2033³â 438¾ï ´Þ·¯·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå¿¡´Â ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ¿¹¹æ ¹× ¿ÏÈ­¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â Ä¡·áÁ¦ÀÇ °³¹ß, »ý»ê ¹× À¯ÅëÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀå¿¡´Â ¸é¿ª¿ä¹ý, Ç×È÷½ºÅ¸¹ÎÁ¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦ ¹× »ý¹°ÇÐÀû Á¦Á¦°¡ Æ÷ÇԵǾî ÀÖÀ¸¸ç, ²É°¡·ç ¾Ë·¹¸£±â¿¡¼­ ½É°¢ÇÑ ¾Æ³ªÇʶô½Ã½º±îÁö ±¤¹üÀ§ÇÑ Áõ»ó¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±âÀÇ À¯º´·ü Áõ°¡, »ý¸í°øÇÐÀÇ Áøº¸, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖÀ¸¸ç, Å« ¼ºÀå ÀáÀç·Â°ú Çõ½ÅÀÇ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀåÀº ¼¼°è ¾Ë·¹¸£±â Áúȯ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í À¯º´·ü¿¡ °ßÀÎµÇ¾î °ßÁ¶ÇÑ È®´ë¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÇÇÇÏ ¸é¿ª ¿ä¹ý(SCIT)Àº Àå±âÀûÀÎ ¾Ë·¹¸£±â °ü¸®¿¡¼­ È¿´ÉÀ» Æò°¡ÇÏ°í ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¼³ÇÏ ¸é¿ª¿ä¹ý(SLIT)Àº ºñħ½ÀÀûÀÎ ¼ºÁú°ú ȯÀÚÀÇ ÄÄÇöóÀ̾𽺿¡ ÀÇÇØ ÁöÁö¸¦ ¸ðÀ¸°í, µÎ ¹øÂ°·Î ½ÇÀûÀÌ ³ôÀº ÇÏÀ§ ºÎ¹®À¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç °í±Þ ÀÇ·á ÀÎÇÁ¶ó¿Í ³ôÀº ¾Ë·¹¸£±â Áúȯ ÀÌȯÀ²¿¡ ¹Ð·Á ÀÖ½À´Ï´Ù. À¯·´Àº À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ¾Ë·¹¸£±â Ä¡·á ¿¬±¸ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç ºÏ¹Ì¿¡ À̾î ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Àα¸ ±ÞÁõ°ú ÀÇ·á ÅõÀÚ Áõ°¡°¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ âÃâÇϰí Áß±¹°ú Àεµ°¡ ÁÖ¿ä °øÇå±¹À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ½ÃÀå Á¡À¯À²À» ¾ò°í ¼¼°è ¾Ë·¹¸£±â ȯÀÚÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ±â¼ú Çõ½Å°ú Àü·«Àû Á¦ÈÞ°¡ ¸Å¿ì Áß¿äÇÏ´Ù´Â °ÍÀ» °­Á¶ÇÕ´Ï´Ù. ½ÃÀåÀÇ ¿ªµ¿ÀûÀÎ »óȲÀº ±ÔÁ¦ »óȲÀÇ º¯È­¿Í ¼ÒºñÀÚÀÇ ÃëÇâ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÀûÀÀÀ» ¿ä±¸ÇÕ´Ï´Ù.

2023³â ½ÃÀå ±Ô¸ð´Â 3¾ï 2,000¸¸È¸ Åõ¿©·Î ÃßÁ¤µÇ¸ç ¿Õ¼ºÇÑ ¼ö¿ä°¡ Ư¡ÀÔ´Ï´Ù. ¼³ÇÏ ¸é¿ª¿ä¹ý ½ÃÀå Á¡À¯À²ÀÌ 45%·Î °¡Àå ³ô°í, À̾ ÇÇÇÏ ¸é¿ª¿ä¹ýÀÌ 30%, ±âŸ Ä¡·á¹ýÀÌ 25%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ºÐÆ÷´Â ºñħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿Í ¼¼°è ¾Ë·¹¸£±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î À̾îÁý´Ï´Ù. ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â ALK-Abello, Stallergenes Greer, Allergy Therapeutics plc µîÀÌ ÀÖÀ¸¸ç, °¢°¢ Çõ½ÅÀûÀÎ Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» Ȱ¿ëÇÏ¿© °æÀï ¿ìÀ§¸¦ À¯ÁöÇϰí ÀÖ½À´Ï´Ù.

°æÀï ±¸µµ´Â Àü·«Àû ÆÄÆ®³Ê½Ê°ú »ý¹° Á¦Á¦ÀÇ Áøº¸¿¡ ÀÇÇØ Çü¼ºµË´Ï´Ù. ƯÈ÷ FDA¿Í EMA¿¡ ÀÇÇÑ ±ÔÁ¦ÀÇ ¿µÇâÀº ½ÃÀå ÁøÀÔ°ú ±ÔÁ¤ Áؼö¸¦ °áÁ¤Çϴµ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ÃÀåÀº R&D ÅõÀÚ Áõ°¡¿Í ¾Ë·¹¸£±â °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2033³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 10%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¹× µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ ºñÁî´Ï½º ±âȸµµ ÀÖÀ¸¸ç, ¹Ì·¡ÀÇ Àü¸ÁÀº ¿©ÀüÈ÷ À¯¸ÁÇÕ´Ï´Ù. ±×·¯³ª ¼±Áø Áö¿ªÀÇ ±ÔÁ¦ Àå¾Ö¹°°ú ½ÃÀå Æ÷È­¿Í °°Àº ¹®Á¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. ȯÀÚ ¸ð´ÏÅ͸µ°ú Ä¡·á °³º°È­¿¡¼­ AIÀÇ ÅëÇÕÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº Áö¿ª Â÷À̰¡ Å®´Ï´Ù. ºÏ¹Ì´Â ¾Ë·¹¸£±âÀÇ À¯º´·üÀÌ ³ô°í ÷´Ü ÀÇ·á ÀÎÇÁ¶ó·Î ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº °ßÁ¶ÇÑ R&D Ȱµ¿À» ÅëÇØ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÎÁöµµ Çâ»ó°ú Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ °¡¿ë¼ºÀ¸·Î ÇýÅÃÀ» ´©¸®°í ½ÃÀå¿¡¼­ÀÇ ¸®´õ½ÊÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

À¯·´Àº µ¶Àϰú ¿µ±¹À» ¼±µÎ·Î ºÏ¹Ì µÚ¸¦ À̾°í ÀÖ½À´Ï´Ù. ÀÌ ³ª¶óµéÀº ÃÖ÷´Ü Ä¡·á¹ý°ú ȯÀÚ Á᫐ Á¢±Ù¹ýÀ» °­Á¶ÇÕ´Ï´Ù. À¯·´ ½ÃÀåÀº °­·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú »ý¸í°øÇп¡ ´ëÇÑ ¾öû³­ ÅõÀÚ¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖÀ¸¸ç, ¾Ë·¹¸£±â Ä¡·áÁ¦ÀÇ ±Þ¼ÓÇÑ Áøº¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ë·¹¸£±â À¯º´·ü Áõ°¡¿Í ÀÇ·á Á¢±ÙÀÇ °³¼±¿¡ ÈûÀÔ¾î ´«ºÎ½Å ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. Áß±¹°ú ÀϺ»Àº ÁÖ¿ä ±¹°¡À̸ç ȯÀÚ ¼ö Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ´É·Â°ú Ä¡·á ¿É¼ÇÀ» °­È­ÇÏ´Â ³ë·ÂÀº ÀÌ Áö¿ª ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â Á¡Â÷ °ßÀηÂÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÇ·á ÁöÃâ Áõ°¡¿Í °è¸ù Ȱµ¿ÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºê¶óÁú°ú ³²¾ÆÇÁ¸®Ä«´Â ÀÇ·á ÀÎÇÁ¶ó °­È­¿Í ¾Ë·¹¸£±â Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó¿¡ ÁÖ·ÂÇÏ´Â ÁÖ¸ñÇÒ¸¸ÇÑ °øÇå±¹ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå Àü¸Á

Á¦5Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå Àü·«

Á¦6Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð

Á¦7Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : À¯Çüº°

Á¦8Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : Á¦Ç°º°

Á¦9Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°

Á¦11Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°

Á¦12Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦13Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : Çüź°

Á¦14Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå : ½ºÅ×ÀÌÁöº°

Á¦15Àå ¾Ë·¹¸£±â Ä¡·áÁ¦ ½ÃÀå :Áö¿ªº°

Á¦16Àå °æÀï ±¸µµ

Á¦17Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The allergy therapeutics market is anticipated to expand from $21.7 billion in 2023 to $43.8 billion by 2033, reflecting a CAGR of 7.3%.

The Allergy Therapeutics Market encompasses the development, production, and distribution of treatments aimed at preventing or alleviating allergic reactions. This market includes immunotherapy, antihistamines, corticosteroids, and biologics, addressing conditions ranging from hay fever to severe anaphylaxis. It is driven by increasing prevalence of allergies, advancements in biotechnology, and a growing focus on personalized medicine, offering significant growth potential and innovation opportunities.

The Allergy Therapeutics Market is witnessing robust expansion, driven by heightened awareness and prevalence of allergic conditions globally. Subcutaneous Immunotherapy (SCIT) leads the market, attributed to its efficacy in long-term allergy management. Sublingual Immunotherapy (SLIT) emerges as the second-highest performing sub-segment, gaining traction due to its non-invasive nature and patient compliance. Regionally, North America dominates the market, propelled by advanced healthcare infrastructure and high allergic disease incidence. Europe follows closely, benefiting from favorable reimbursement policies and a strong focus on research and development in allergy treatments. In the Asia-Pacific region, burgeoning populations and rising healthcare investments create lucrative growth opportunities, with China and India poised as key contributors. These trends underscore the critical importance of innovation and strategic alliances in capturing market share and addressing the evolving needs of allergy sufferers worldwide. The market's dynamic landscape demands continuous adaptation to regulatory changes and consumer preferences.

In 2023, the market was characterized by a robust demand, with the market volume estimated at 320 million doses. The sublingual immunotherapy segment commands the largest market share at 45%, followed by subcutaneous immunotherapy at 30%, and other treatment modalities at 25%. This distribution is driven by the increasing preference for non-invasive treatments and the growing prevalence of allergic diseases globally. Key players in this domain include ALK-Abello, Stallergenes Greer, and Allergy Therapeutics plc, each leveraging innovative product pipelines to maintain competitive advantage.

The competitive landscape is shaped by strategic partnerships and advancements in biologics. Regulatory influences, particularly from the FDA and EMA, are pivotal in determining market entry and compliance. The future outlook remains promising, with opportunities in personalized medicine and digital health solutions. However, challenges such as regulatory hurdles and market saturation in developed regions persist. The integration of AI in patient monitoring and treatment personalization is anticipated to enhance market growth.

The market exhibits significant regional variations. North America dominates due to high prevalence of allergies and advanced healthcare infrastructure. The United States leads, driven by robust research and development activities. This region benefits from increased awareness and availability of innovative treatments, reinforcing its market leadership.

Europe follows closely, with countries like Germany and the United Kingdom spearheading growth. These nations emphasize cutting-edge therapies and patient-centered approaches. The European market is bolstered by strong regulatory frameworks and substantial investments in biotechnology, facilitating rapid advancements in allergy therapeutics.

The Asia Pacific region is experiencing impressive growth, propelled by rising allergy incidences and improved healthcare access. China and Japan are key players, investing in research and development to cater to their growing patient base. Efforts to enhance diagnostic capabilities and treatment options are driving market expansion in this region.

Latin America and the Middle East & Africa regions are gradually gaining traction. Increased healthcare spending and awareness initiatives are contributing to market growth. Brazil and South Africa are notable contributors, focusing on enhancing healthcare infrastructure and accessibility to allergy treatments.

Key Companies

ALK- Abello, Stallergenes Greer, Circassia Pharmaceuticals, DBV Technologies, Allergy Therapeutics, HAL Allergy Group, Aimmune Therapeutics, Leti Pharma, Boehringer Ingelheim Vetmedica, Aravax, Inmunotek, Anaptys Bio, Anergis, Adamis Pharmaceuticals, Intrommune Therapeutics, Alladapt Immunotherapeutics, Cambridge Allergy, Allovate Therapeutics, ASIT biotech, Allergy Amulet

Sources

World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, National Institutes of Health, Centers for Disease Control and Prevention, American Academy of Allergy, Asthma & Immunology, World Allergy Organization, European Academy of Allergy and Clinical Immunology, Global Initiative for Asthma, National Institute of Allergy and Infectious Diseases, Asthma and Allergy Foundation of America, Allergy and Asthma Network, International Food Allergy & Anaphylaxis Alliance, British Society for Allergy & Clinical Immunology, Australasian Society of Clinical Immunology and Allergy, International Primary Care Respiratory Group, International Conference on Allergy and Clinical Immunology, European Respiratory Society Annual Congress, American Thoracic Society International Conference, World Congress of Asthma

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Allergy Therapeutics Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Allergy Therapeutics Market Outlook

5: Allergy Therapeutics Market Strategy

6: Allergy Therapeutics Market Size

7: Allergy Therapeutics Market, by Type

8: Allergy Therapeutics Market, by Product

9: Allergy Therapeutics Market, by Services

10: Allergy Therapeutics Market, by Technology

11: Allergy Therapeutics Market, by Application

12: Allergy Therapeutics Market, by End User

13: Allergy Therapeutics Market, by Mode

14: Allergy Therapeutics Market, by Stage

15: Allergy Therapeutics Market, by Region

16: Competitive Landscape

17: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â